Clinical Trials & Pipeline
News & Events
Mirna is a clinical-stage biopharmaceutical and immuno-oncology company developing a broad pipeline of leading microRNA-based oncology therapeutics, the first to be tested in cancer patients.
LEARN MORE ABOUT US
MRX34, Mirna’s lead product candidate, is the first microRNA mimic to enter clinical testing.
LEARN MORE ABOUT OUR CLINICAL TRIALS AND PIPELINE
April 30, 2015
Mirna Secures $41.8 Million Series D Financing to Advance Oncology microRNA Pipeline
April 21, 2015
Mirna Presents Interim Phase 1 Data on First-in-Class, First-in-Clinic microRNA-34 mimic, MRX34, at the 2015 Annual Meeting of the American Association for Cancer Research
VIEW ALL NEWS
© 2014 Mirna Therapeutics, Inc. All Rights Reserved.